EnLiSense CCM To Advance IBD Care with Innovative Sweat Sensor Studies, Teams Up with Leading Clinicians
Patients and clinicians are now actively being enrolled in these studies, marking a pivotal phase in EnLiSense's journey towards revolutionizing chronic disease management.
- Patients and clinicians are now actively being enrolled in these studies, marking a pivotal phase in EnLiSense's journey towards revolutionizing chronic disease management.
- The IBD Aware system, a cornerstone of EnLiSense's innovative approach, continuously monitors key inflammatory biomarkers by gently resting on a patient’s skin sampling just nano-liters of passive sweat.
- This non-invasive, wearable technology empowers both clinicians and patients with real-time data, facilitating personalized, data-driven, proactive management of chronic diseases like IBD.
- Dr. Sriram Muthukumar, CEO of EnLiSense CCM, reflects on the early findings, stating, "The initial validation data is indeed very encouraging.